Spectrum Pharmaceuticals announced the commercial launch of Marqibo (vincristine sulfate liposome injection). Spectrum obtained marketing rights to Marqibo through the recent acquisition of Talon Therapeutics.
Marqibo is a sphingomyelin/cholesterol liposome-encapsulated formulation of vincristine that is indicated for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following ≥2 anti-leukemia therapies.
The liposome encapsulation technology has been shown to provide prolonged circulation of vincristine in the blood.
Marqibo can be accessed through Spectrum Therapy Access Resources (STAR) which is a reimbursement support, co-pay assistance, and patient assistance program designed to help patients and healthcare professionals gain appropriate access to drugs.
For more information call or visit Marqibo.com.